Remicade News and Research

RSS

A new test could save arthritis patients time, money, and pain. But will it be used?

Erinn Maury knew Remicade wasn't the right drug for Patti Schulte, a rheumatoid arthritis patient the physician saw at her Millersville, Maryland, practice. Schulte's swollen, painful joints hadn't responded to Enbrel or Humira, two drugs in the same class.

20 Dec 2023

Two anti-inflammatory drugs reduce deaths in severe COVID-19 patients

Two anti-inflammatory drugs, abatacept and infliximab, reduced deaths among patients hospitalized with severe COVID-19, according to a national study led by Washington University School of Medicine in St. Louis. William G. Powderly, MD, (right) who led the large clinical trial, discusses patient conditions with Maanasi Samant, MD, in the intensive care unit at Barnes-Jewish Hospital, one of the major trial sites, during the COVID-19 pandemic.

10 Jul 2023

Patients squeezed in fight over who gets to bill for pricey infusion drugs

Health insurers and medical providers are battling over who should supply high-cost infusion drugs for patients, with the tussle over profits now spilling into statehouses across the country.

5 Jul 2023

Decisions by CVS and Optum panicked thousands of their sickest patients

The fear started when a few patients saw their nurses and dietitians posting job searches on LinkedIn.

7 Feb 2023

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Biosimilar drugs are cheaper than biologics. Are they similar enough to switch?

It took years for Elle Moxley to get a diagnosis that explained her crippling gastrointestinal pain, digestion problems, fatigue, and hot, red rashes.

23 Sep 2021

NIH launches adaptive Phase 3 clinical trial to test immune modulator drugs in COVID-19 patients

The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19.

16 Oct 2020

Study: Biologic therapy did not reduce IBD-related hospitalizations and surgeries

The introduction of infliximab, the first biologic therapy approved for the treatment of inflammatory bowel diseases, did not result in lower rates of hospitalizations or intestinal surgeries among patients living with IBD in Ontario, according to a study published by authors from several Canadian hospitals and ICES in the journal Gut.

13 Jun 2019

New computational framework reveals impact of arthritis drugs on gene expression

A new computational framework has revealed key differences between four rheumatoid arthritis medications and their impact on biological pathways in mice.

10 May 2019

Top policy expert’s ties to giant drugmaker often go unstated

When Dr. Mark McClellan sat for an in-depth 30-minute question-and-answer session at an April health policy forum, the audience was filled with top researchers, advocates and Capitol Hill staffers eager to hear what insight the former head of the Food and Drug Administration would dispense.

29 Jun 2018

Biosimilar competition may offer hope for cheaper, better psoriasis treatments in the future

A new study by iData Research estimates that there are nearly 150,000 new cases of psoriasis every year in the United States, affecting 2.2% of the population.

20 Jun 2018

Biosimilars, biologics and new legal challenges for RA treatments

Early last winter, Pfizer launched its new rheumatoid arthritis treatment, Inflectra, pricing it 15 percent below the $4,000-a-dose wholesale price of Remicade, the drug for which it is a close copy.

22 Dec 2017

Without price breaks, rural hospitals struggle to stock costly, lifesaving drugs

Hospital pharmacist Mandy Langston remembers when Lulabelle Berry arrived at Stone County Medical Center's emergency department last year.

18 Sep 2017

Scientists rewire mouse stem cells to fight inflammation caused by arthritis

Using new gene-editing technology, researchers have rewired mouse stem cells to fight inflammation caused by arthritis and other chronic conditions.

28 Apr 2017

Generic biologic drugs appear to be as effective as brand-name versions

Generic forms of a biologic drug used to treat rheumatoid arthritis, inflammatory bowel disease and psoriasis appear to be as safe and effective as their brand-name counterparts, a new Johns Hopkins Bloomberg School of Public Health analysis suggests.

2 Aug 2016

Celltrion Healthcare commits to develop lab tests for evidence-based decision-making in anti-TNF treatment

Celltrion Healthcare, a global biopharmaceutical company, today announced its research commitment to develop laboratory tests that will determine both drug and anti-drug antibody levels in the blood, enabling physicians to identify when patients on an anti-tumour necrosis factor drug require a change of dose or a switch to a different treatment in the class.

5 Jul 2016

Antibody-positive patients treated with infliximab less likely to benefit from infliximab biosimilar

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that when antibodies develop in response to the biological treatment Remicade (infliximab), they also cross-react with the biosimilar of infliximab (CT-P13: Inflectra or Remsima).

10 Jun 2016

New study explores factors that affect Medicare patient’s adherence to psoriasis biologic therapies

About half of Medicare patients who start taking biologic therapies for moderate to severe plaque psoriasis stop within a year, according to a new study led by researchers from the Perelman School of Medicine at the University of Pennsylvania.

26 Apr 2016

Inflectra (infliximab-dyyb) approved for multiple indications

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

6 Apr 2016